Ann: Antisense Therapeutics transitions to new Board Chair, page-103

Then what was the point in specifying the date on this ann? After over 20 years at the helm of the company is it normal he still doesn’t get right how things happen in the bio world ? :

ASX Announcement26 May 2021
Manufacture of ATL1102 clinical supplies for Phase IIb trial in DMD•

Manufacture of ATL1102 active pharmaceutical ingredient (API) batch completed• Formulation into injectable product for use in the Phase IIb trial completed• Drug Product testing underway for release for use in clinical trialsAntisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], (the Company) is _please to provide the following progress update on the manufacture of clinical supplies for its planned Phase IIb clinical trial of ATL1102 in non-ambulant Duchenne (DMD) patients.

The manufacture of ATL1102 active pharmaceutical ingredient (API) for the Phase IIb trial was undertaken in North America by Nitto Denko Avecia (Avecia) a contract manufacturing organization (CMO) with over 27 years of experience in oligonucleotide (antisense) development and production. Avecia has supported the commercial launch of oligonucleotide products since 2004 and offers complete continuity of supply up to multiple kilograms per batch with its large scale and commercial capabilities in support of advanced clinical trials and subsequent commercial supply.Upon completion of the manufacture of this batch of API by Avecia last month, the material was then shipped to Contract, Parenteral (injectable) Drug Product Manufacturer Pyramid Laboratories in Costa Messa, Southern California and formulated into injectable product for use in the Phase IIb trial. This formulated injectable product (Drug Product or DP) is currently undergoing finished product release testing for clinical use,**with results anticipated later next month.**

Mark Diamond CEO of Antisense Therapeutics said: “We are very pleased with how the manufacture of clinical supplies for our planned Phase IIb trial of ATL1102 has proceeded particularly given the challenges that have presented to all CMO’s during the global covid pandemic. We are indeed fortunate to be partnered with such high quality CMOs that have a deep experience with antisense drugs and both of which we have been working with for over 15 years and that can support manufacture all the way through to commercial sale of product”.
This announcement has been authorised for release by the CEO.